Clinical Investigation
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters and relevant clinical factors in peripheral T-cell lymphoma, not otherwise specified
Jiang Chong, Lai Ruihe, Teng Yue, Ding Chongyang
Published 2022-06-25
Cite as Chin J Nucl Med Mol Imaging, 2022, 42(6): 347-351. DOI: 10.3760/cma.j.cn321828-20210218-00034
Abstract
ObjectiveTo explore the prognostic role of baseline 18F-FDG PET/CT metabolic parameters for patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).
MethodsFrom February 2010 to January 2019, 47 PTCL-NOS patients (29 males, 18 females, age: (59.7±13.6) years) from Nanjing Drum Tower Hospital were retrospectively enrolled. Each patient underwent baseline 18F-FDG PET/CT imaging before treatment. The total metabolic tumor volume (TMTV) and total lesion glycolysis (TLG) were computed by using the margin threshold of 41% SUVmax. Kaplan-Meier survival analysis, univariate and multivariate Cox proportional hazards regression models were used to evaluate progression-free survival (PFS) and overall survival (OS).
ResultsOver the follow-up of 5-119 months, 25 patients had disease progression, including 24 deaths. SUVmax (hazard ratio (HR)=8.581, 95% CI: 1.950-37.764, P=0.004), TMTV(HR=9.677, 95% CI: 3.521-26.593, P<0.001), TLG(HR=3.647, 95% CI: 1.245-10.682, P<0.001) and prognostic index for T-cell lymphoma (PIT; HR=4.593, 95% CI: 1.792-11.773, P=0.002) were significant predictors of PFS and OS(HR=8.720, 95% CI: 1.982-83.354, P=0.004; HR=9.325, 95% CI: 3.423-25.408, P<0.001; HR=3.439, 95% CI: 1.170-10.110, P<0.001; HR=4.437, 95% CI: 1.728-11.393, P=0.002). After multivariate analysis, TMTV was the independent predictor of PFS (HR=4.371, 95% CI: 1.066-16.541, P<0.001) and OS (HR=4.978, 95% CI: 1.123-21.329, P<0.001). The substratification analysis showed that patients with high TMTV(≥168.3 cm3) had worse prognosis than those with low TMTV (<168.3 cm3) for PFS (χ2=14.60, P<0.001) and OS (χ2=16.81, P<0.001) in low PIT (0-1) group, while patients with high TMTV had worse prognosis than those with low TMTV for PFS (χ2=4.09, P=0.043) in high PIT (≥2) group.
ConclusionsBaseline PET/CT metabolic parameters including SUVmax, TMTV, TLG and PIT are able to predict survival in PTCL-NOS patients. TMTV is the independent predictor of PFS and OS, which can substratify PTCL-NOS patients in PIT group.
Key words:
Lymphoma, T-cell, peripheral; Positron-emission tomography; Tomography, X-ray computed; Fluorodeoxyglucose F18; Prognosis
Contributor Information
Jiang Chong
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Lai Ruihe
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Teng Yue
Department of Nuclear Medicine, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China
Ding Chongyang
Department of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
